THERAPY DOSSIER · th-dfb15ed53a2c

Compound 1c, (E)-N'-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32380016 ↗2020Reported benefit

(E)-N'-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide protecting rat heart tissues from isoproterenol toxicity: Evidence from in vitro and in vivo tests.

RatChemical/toxinWistarMalen = Four groupsOral150 microgram/kg body weightPretreatment for 7 days before isoproterenol

Model: Isoproterenol-induced myocardial infarction (85 mg/kg subcutaneously at 24 h intervals on days 6 and 7)

Pretreatment with compound 1c improved the electrocardiogram pattern, significantly reduced cardiac dysfunction markers raised by isoproterenol, and lowered fibrinogen, suggesting an anticoagulant action against thrombosis in acute myocardial infarction.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…